Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.70 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.70 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.70 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.70 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.70 |
| ▸ | AKT1 | P31749 | 8/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.50 |
| ▸ | PRKACA | P17612 | 4/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.50 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.50 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.50 |
| ▸ | PIM1 | P11309 | 3/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.50 |
| ▸ | CLK2 | P49760 | 2/20 | 0.50 |
| ▸ | PRKX | P51817 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4056654 | 0.85 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL4959044 | 0.84 | MKNK2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8675780 | 0.84 | MKNK2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL194810 | 0.82 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30529817 | 0.82 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL621160 | 0.82 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7744103 | 0.79 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL4242133 | 0.78 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL4242134 | 0.78 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5878807 | 0.75 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5616716-A | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds | TARGACEPT, INC. | 1997-04-01 | — | — | US | claimed |
| EP-1997806-A1 | Pahrmaceutical compositions for prevention and treatment of central nervous system disorders | Targacept, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-0873050-B1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS | TARGACEPT INC (US) | 2004-03-10 | — | — | EP | disclosed |
| US-6603011-B1 | Representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine; the prevention and treatment of CNS disorders which have been attributed to neurotransmitter system dysfunction | TARGACEPT, INC. | 2003-08-05 | — | — | US | disclosed |
| US-6555684-B2 | A pyridine or pyrimidine derivatives containing primary, secondary or tertiary amine group | TARGACEPT, INC. | 2003-04-29 | — | — | US | disclosed |
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | CALDWELL WILLIAM SCOTT (US) | 2002-03-14 | — | — | US | disclosed |
| US-6107298-A | ADMINISTERING AN AMINE SUBSTITUTED PYRIMIDINE OR PYRIDINE COMPOUND | BENCHERIF MEROUANE (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0873050-A4 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS | REYNOLDS TOBACCO CO R (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0900200-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0873050-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1998-10-28 | — | — | EP | disclosed |
| EP-0801646-A4 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | REYNOLDS TOBACCO CO R (US) | 1998-03-25 | — | — | EP | disclosed |
| WO-1997040011-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R. J. REYNOLDS TOBACCO COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| EP-0801646-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1997-10-22 | — | — | EP | disclosed |
| US-5616716-A | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds | TARGACEPT, INC. | 1997-04-01 | — | — | US | disclosed |
| US-5616716-A | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds | TARGACEPT, INC. | 1997-04-01 | — | — | US | disclosed |
| US-5604231-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS, DOPAMINERGIC AGENTS; SIDE EFFECT REDUCTION | TARGACEPT, INC. | 1997-02-18 | — | — | US | disclosed |
| US-5597919-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS RESULTING FROM NEUROTRANSMITTER DYSFUNCTION | TARGACEPT, INC., A CORPORATION OF DELAWARE | 1997-01-28 | — | — | US | disclosed |
| WO-1996020929-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1996020599-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | PMP22, AANAT, CHAT | CHRNB2 17/4885CHRNA4 8/4885CHRNB4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.